Anadys Pharmaceuticals, Inc.is a new generation drug discovery company committed to applying an integrated approach that combines biology and chemistry to develop new small molecule therapeutics. The Company's initial therapeutic focus is in anti-infectives. Anadys has developed and implemented proprietary technologies (GATE(TM)) to identify novel antibacterial targets. The Company augments this set of targets with additional antibacterial and antiviral targets using its dominant expertise in Riboproteomics(TM), a phrase coined by the Company to describe the systematic study of RNA-related targets.
